首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Molecular quantification of bacteria from respiratory samples in patients with suspected ventilator-associated pneumonia
【24h】

Molecular quantification of bacteria from respiratory samples in patients with suspected ventilator-associated pneumonia

机译:疑似呼吸机相关性肺炎患者呼吸道细菌的分子定量分析

获取原文
获取原文并翻译 | 示例
           

摘要

Ventilator-associated pneumonia (VAP) is the most common infection in critically ill patients. Initial antibiotic therapy is often broad spectrum, which promotes antibiotic resistance so new techniques are under investigation to obtain early microbiological identification and quantification. This trial compares the performance of a new real-time quantitative molecular-based method with conventional culture in patients with suspected VAP. Patients with suspected VAP who were ventilated for at least 48 h were eligible. An endotracheal aspirate (ETA) and a bronchoalveolar lavage (BAL) were performed at each suspected VAP episode. Both samples were analysed by conventional culture and molecular analysis. For the latter, bacterial DNA was extracted from each sample and real-time PCR were run. In all, 120 patients were finally included; 76% (91) were men; median age was 65 years, and clinical pulmonary infection score was >= 6 for 73.5% (86) of patients. A total of 120 BAL and 103 ETA could be processed and culture results above the agreed threshold were obtained for 75.0% (90/120) of BAL and 60.2% (62/103) of ETA. The main isolated bacteria were Staphylococcus aureus, Pseudomonas aeruginosa and Haemophilus influenzae. Performancewas 89.2% (83.2% e93.6%) sensitivity and 97.1% (96.1% e97.9%) specificity for BAL samples and 71.8% (61.0% e81.0%) sensitivity and 96.6% (95.4% e97.5%) specificity for ETA samples when the molecular biology method was compared with conventional culture method (chosen as reference standard). This new molecular method can provide reliable quantitative microbiological data and is highly specific with good sensitivity for common pathogens involved in VAP. (C) 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
机译:呼吸机相关性肺炎(VAP)是重症患者中最常见的感染。最初的抗生素治疗通常是广谱的,可促进抗生素耐药性,因此正在研究新技术以早期鉴定和定量微生物。该试验将新型实时定量基于分子的方法与常规培养方法在可疑VAP患者中的效果进行了比较。怀疑VAP至少通气48 h的患者符合条件。在每个可疑的VAP发作时进行气管内抽吸(ETA)和支气管肺泡灌洗(BAL)。通过常规培养和分子分析对两个样品进行分析。对于后者,从每个样品中提取细菌DNA并进行实时PCR。最终共纳入120例患者。 76%(91)是男性;中位年龄为65岁,并且73.5%(86)的患者临床肺部感染评分> = 6。总共可以处理120个BAL和103个ETA,并且获得75.0%(90/120)的BAL和60.2%(62/103)的ETA的培养结果超出议定的阈值。分离出的主要细菌是金黄色葡萄球菌,铜绿假单胞菌和流感嗜血杆菌。对于BAL样品,性能分别为89.2%(83.2%e93.6%)和97.1%(96.1%e97.9%)特异性,71.8%(61.0%e81.0%)和96.6%(95.4%e97.5%)将分子生物学方法与常规培养方法(选择作为参考标准)进行比较时对ETA样品的特异性。这种新的分子方法可以提供可靠的定量微生物数据,并且对VAP中涉及的常见病原体具有很高的特异性和良好的敏感性。 (C)2016欧洲临床微生物学和传染病学会。由Elsevier Ltd.出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号